Three Pt(ii) complexes based on thiosemicarbazone: synthesis, HSA interaction, cytotoxicity, apoptosis and cell cycle arrest

Abstract

Three new Pt-based complexes with better IC50 values than cisplatin displayed different cytotoxicity, cycle arrest and cell uptake manners.

Advances in thiosemicarbazone metal complexes as anti-lung cancer agents

“…Current research shows the action mechanism of involves the hydrolysis of cisplatin in the human body, removal of two chlorine atoms and binding to two purines on the genomic DNA and twisting the DNA double helix structure, thereby inhibiting DNA replication and transcription and ultimately causing cancer cell apoptosis ( Pahontu et al, 2016a ). The quenching mechanism of HSA by three thiosemicarbazide Pt (II) complexes ( 85–87 ) may be a static binding mode and impact the microenvironment of tryptophan residues in HSA ( Scheme 9 ) ( Lin et al, 2017 ). These three complexes show significant anti-proliferative activity (IC 50 , 2.8–9.6 μM) against the NCI-H460 cell line.…”

Antitumor effects of new glycoconjugated PtII agents dual-targeting GLUT1 and Pgp proteins

“…S9 †) have been reported in our previous work. 43 Herein, we further carried out glycosylation modification at the N(4) position to obtain potential glycoconjugated Pt II anticancer agents, as shown in Fig. 1.…”

Michael addition-driven synthesis of cytotoxic palladium(ii) complexes from chromone thiosemicarbazones: investigation of anticancer activity throughin vitroandin vivostudies

“…Even though 70% of people with cancer are subjected to these Pt-based drugs, these have numerous drawbacks, such as neuro-and nephro-toxicity and drug resistance against many cancer cell lines. [3][4][5][6] These factors provoke researchers to develop better drugs that help to minimize toxicity and maximize the drug action against cancer cell lines.…”